Lorbrena and Vitrakvi
Determining the interaction of Lorbrena and Vitrakvi and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme as well as the efflux transporter. When a single 100 mg dose of larotrectinib was coadministered with rifampin, a potent CYP450 3A4 and P-gp inducer, larotrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 71% and 81%, respectively, compared to administration of larotrectinib alone. Reduced efficacy of larotrectinib may occur. The interaction has not been studied with other, less potent inducers. MANAGEMENT: The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers. Some authorities advise that concomitant use of larotrectinib with moderate CYP450 3A4 and/or P-gp inducers should be avoided (UK). Alternative treatments may be required if an interaction is suspected. References "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme as well as the efflux transporter. When a single 100 mg dose of larotrectinib was coadministered with rifampin, a potent CYP450 3A4 and P-gp inducer, larotrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 71% and 81%, respectively, compared to administration of larotrectinib alone. Reduced efficacy of larotrectinib may occur. The interaction has not been studied with other, less potent inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers. Some authorities advise that concomitant use of larotrectinib with moderate CYP450 3A4 and/or P-gp inducers should be avoided (UK). Alternative treatments may be required if an interaction is suspected.
- "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lorbrena-Vitrakvi (Larotrectinib Capsules)
- Lorbrena-Vitrakvi (Larotrectinib Oral Solution)
- Lorbrena-Vitrase
- Lorbrena-Vitrase injection
- Lorbrena-Vitravene
- Lorbrena-Vitron-C
- Vitrakvi-Lorcaserin
- Vitrakvi-Lorcaserin Extended-Release Tablets
- Vitrakvi-Lorcaserin Hydrochloride
- Vitrakvi-Lorcaserin Tablets
- Vitrakvi-Lorcet
- Vitrakvi-Lorcet Plus